

ResMed launches Next-Gen AirSenseTM 11 CPAP in Singapore elevating Digital Health in Sleep Apnoea treatment

06 November 2024 | News

ResMed's 2024 Global Sleep Survey revealed that nearly 40% of Singaporeans only get one to three good nights' sleep each week



ResMed, a global leader in sleep and digital health solutions, launched its next-generation Continuous Positive Airway Pressure (CPAP) device, the **AirSense™ 11**, on 6 Nov at ResMed's Advanced Manufacturing Centre in Tuas, Singapore. A suite of advanced features will simplify the treatment and management of obstructive sleep apnoea (OSA) for people suffering from repeated sleep apnoeas. The AirSenseTM 11 is designed and produced at ResMed's Advanced Manufacturing Centre at Tuas site.

The AirSense[™] 11, a patient-centered design combines powerful therapy with smart digital tools that make nightly use easier and empower clinicians with enhanced support for patients. The launch of ResMed's digital sleep health solutions in Singapore marks an important step towards transforming sleep health worldwide.

"Leveraging digital health innovations can enhance sleep quality for people suffering from conditions like sleep apnoea, contributing to their overall physical and mental well-being," said Carlos Montiel, Vice President and General Manager, Southeast Asia and South Korea at ResMed.

"In fast-paced and competitive cities like Singapore, the importance of quality sleep cannot be overstated – yet it's often difficult to achieve. Our proven, innovative sleep health technologies can help combat sleep deprivation, helping individuals improve their quality of life."

ResMed's 2024 Global Sleep Survey revealed that nearly 40% of Singaporeans only get one to three good nights' sleep each week, and by 2030, ResMed aims to serve 500 million people suffering from sleep disorders.

Innovative CPAP device, the AirSenseTM 11 features:

Personal Therapy Assistant: An intuitive, step-by-step tutorial available through the myAir app to help users set up their devices, reducing setup time and acclimating to therapy pressure that improves ease of use. The device is built with intuitive touchscreen interface for an seemless operation similar to smarphones.

Care Check-In: Provides personalised feedback and guidance to patient's questionaries accessible via the myAir app and the device screen. With the user's consent, healthcare providers can see their patients' responses in AirView, providing another fast, virtual way to monitor patients. In addition, the device allows users to try different pressure levels, helping them acclimate to therapy more comfortably.

Proprietary therapy algorithms: Auto-adjusting PAP therapy (AutoSet or APAP) delivers customised breath-by-breath therapy, including specialised settings for women through the AutoSet for Her mode.

Remote and self-monitoring tools: The AirSenseTM 11, also gives access to myAir (patient engagement app) and AirView (remote monitoring platform for clinicians) - which together helps bring overall patient adherence to as high as 87%. The myAir app tracks the amount of time patients spend using CPAP therapy, number of sleep apnoea events per hour, mask leak, and the number of times a mask was removed, providing nightly data on breathing, coaching tips, and support directly to their phone. AirView provides a secure, cloud-based patient management system for online patient monitoring that enables healthcare professionals to quickly access patient data, share clinical insights with other health professionals, improve care and reduce costs related to patient follow-up.